PRESS RELEASE
News
-
-
-
PRESS RELEASE
The Next 150 Inks 6-Year Agreement With Microsoft for 95,000 High-Quality Biochar Carbon Removal Credits
The Next 150 signs a six-year purchase agreement with Microsoft for carbon removal credits from its biochar plant in Guanajuato, Mexico, further establishing itself in the carbon removal industry -
PRESS RELEASE
01 Communique Provides Update on Business Developments and First Quarter Fiscal 2024 Results
01 Communique Laboratory Inc. reports Q1 fiscal 2024 results, highlighting reduced losses and operating expenses, and plans to increase revenue through IronCAP™ partnerships. Conference call scheduled to discuss results and business prospects -
PRESS RELEASE
Siyata Further Expands Global Distribution in Agreement with Leading Mobility, Logistics and Infrastructure Conglomerate in the Middle East
Siyata Mobile Inc. expands global distribution of Rugged PTT Handsets and In-Vehicle Devices through a distribution agreement with a leading Middle East group. CEO Seelenfreund highlights growth opportunities for 2024 -
-
-
PRESS RELEASE
Public Health Vaccines Announces Initiation of First Clinical Trial Evaluating Its Marburg Virus Vaccine
Public Health Vaccines, LLC initiates Phase 1 clinical trial for single-dose vaccine against Marburg virus, with BARDA funding up to $72 million for development. Company aims for global preparedness against infectious diseases -
PRESS RELEASE
Amdocs Research Reveals 90% of Service Providers Believe Generative AI is Critical for Achieving Business Goals, But See Significant Challenges with Implementation
Amdocs survey reveals CSPs are in early stages of GenAI implementation. Challenges include data quality and regulation. Automation and benefits expected -
PRESS RELEASE
abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW) Announce Investment Team Update
abrdn announces Dr. Jason Akus as co-lead portfolio manager for their Funds alongside Dr. Daniel Omstead, continuing with existing objectives and strategies. Dr. Omstead to remain in advisory role until September 30, 2024
